Economic evaluation of arsenic trioxide compared to all‐trans retinoic acid + conventional chemotherapy for treatment of relapsed acute promyelocytic leukemia in Canada
Acute promyelocytic leukemia (APL) is an uncommon type of acute leukemia characterized by high early mortality. Current first‐line treatments include all‐trans retinoic acid (ATRA), anthracyclines, and other conventional chemotherapies (CTs). Although APL is generally associated with a good prognosis, about 20% of patients who achieve remission subsequently relapse and are resistant to the previously administrated treatment. The objective of this study was to assess, from a Canadian perspective, the economic impact of arsenic trioxide (ATO) compared to ATRA+CT for treatment of patients with relapsed/refractory APL.
No Supplementary Data
No Article Media